



**List of Cell/Tissue/Gene Products with marketing authorization (MA) in Australia by TGA**  
(Therapeutic Goods Administration)

Name (MA Holder)	Product description and indication(s)	Product category	Date of MA	Current Status	Additional information
<b>Kymriah (Novartis Pharmaceuticals Australia Pty Ltd)</b>	CD19-directed genetically modified autologous T-cell immunotherapy indicated for the treatment of pediatric and young adult patients up to 25 years with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy	Gene Therapy Product	19-Dec-2018	Still in Market	<a href="#">Click Here for Link to TGA Website</a>  <a href="#">Click Here for Link to TGA Website</a>
<b>Chondrocytes - T - Ortho-ACI (Orthocell Pty Ltd)</b>	Autologous cultured chondrocytes for use in treatment of cartilage lesions associated with the knee, patella and ankle	Cell Therapy Product	26-Mar-2017	Still in market	<a href="#">Click Here for Link to TGA Website</a>
<b>IMLYGIC (talimogene laherparepvec) (Amgen Australia Pty Ltd)</b>	Oncolytic immunotherapy derived from a herpes simplex virus-1 genetically engineered to infect and replicate within melanoma cells and to produce GM-CSF for unresectable melanoma	Gene Therapy Product	6-Jun-2016	Still in market	<a href="#">Click Here for Link to TGA Website</a>  <a href="#">Click Here for Link to TGA Website</a>

**List of Cell/Tissue/Gene Products with MA in Canada by Health Canada (March 2018)**

Name (MA Holder)	Product description and indication(s)	Product category	Date of MA	Current Status	Additional information
<b>KYMRIAH (NOVARTIS PHARMACEUTICALS CANADA INC)</b>	CD19-directed genetically modified autologous T-cell immunotherapy indicated for the treatment of pediatric and young adult patients 3 to 25 years with B-cell acute lymphoblastic leukemia (ALL) who are refractory, have relapsed after	Gene Therapy Product	05-Sept2018	In market	<a href="#">Click Here for Link to Health Canada Website</a>

	allogeneic stem cell transplant (SCT) or are otherwise ineligible for SCT, or have experienced second or later relapse and for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.				
<b>Prochymal (MESOBLAST INTERNATIONAL SARL)</b>	Allogeneic ex-vivo cultured adult human mesenchymal stem cells for the management of acute Graft versus Host Disease (aGvHD) in pediatric patients	Cell Therapy Product	02-May-2015	The product was never marketed in Canada	<a href="#">Click Here for Link to Health Canada Website</a>

### List of Cell/Tissue/Gene Products with MA in China by CSFDA (Chinese Food and Drug Administration)

Name (MA Holder)	Product description and indication(s)	Product category	Date of MA	Current Status	Additional information
<b>Gendicine (Shenzhen SiBiono GeneTech Co. Ltd.)</b>	Recombinant adenovirus expressing p53 for treatment of head and neck squamous cell carcinoma	Gene Therapy Product	Oct-2003	Still in market	<a href="#">Click Here</a>

### List of Cell/Tissue/Gene Products with MA in the European Union by European Medicines Agency (EMA)

Name (MA Holder)	Product description and indication(s)	ATMP	Date of MA	Current Status	Additional information
<b>LUXTURNA (Spark Therapeutics Ireland Ltd.)</b>	Adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy	GTMP	23-Nov-2018	Details of MA conditions not displayed at EMA Website as of 30 November 2018	<a href="#">Click Here for Link to Press Release</a>
<b>YESCARTA (Kite Pharma EU B.V.)</b>	CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory diffuse	GTMP	27-Aug-2018	MA under several conditions and obligations: Periodic Safety Update Reports; Availability	<a href="#">Click Here for Link to EMA Website</a>

	large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy				of tocilizumab and site qualification; Educational program; Non-interventional post-authorisation safety study based on a registry until 2038	
<b>KYMRIAH (Novartis Europharm Limited)</b>	CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy	GTMP	27-Aug-2018		Granted MA under additional monitoring until MA under several conditions and obligations: Periodic Safety Update Reports; Availability of tocilizumab and site qualification; Educational program; Several non-interventional post-authorisation safety and efficacy studies based on registries until 2038	<a href="#">Click Here for Link to EMA Website</a>
<b>ALOFISEL (Takeda Pharma A/S)</b>	Expanded allogeneic adipose stem cells as a suspension for injection for the treatment of complex perianal fistulas in patients with Crohn's disease	SCTMP	27-Mar-2018		The company will complete a study to continue to collect information on the effectiveness and safety	<a href="#">Click Here for Link to EMA Website</a>
<b>SPHEROX (CO.DON AG)</b>	Spheroids of human autologous matrix-associated chondrocytes for knee repairing cartilage defects	TEP	10-Jul-2017		MA under several obligations (post-authorization long-term efficacy and safety study, a prospective process validation study and to re-validate the potency assay)	<a href="#">Click Here for Link to EMA Website</a>
<b>ZALMOXIS (MoImed SpA)</b>	Donor's T lymphocytes genetically modified with a suicide gene as a control mechanism for GvHD after haploidentical Bone Marrow transplant	GTMP	18-Aug-2016		Granted MA under conditional approval	<a href="#">Click Here for Link to EMA Website</a>
<b>STRIMVELIS (GSK Trading Services Limited)</b>	Autologous CD34+ cells transduced with a retroviral vector that encodes for the human ADA cDNA sequence for severe combined immunodeficiency due to ADA deficiency	GTMP	26-May-2016		Granted MA under additional monitoring until 2037	<a href="#">Click Here for Link to EMA Website</a>

<b>IMLYGIC (Amgen Europe B.V.)</b>	Oncolytic immunotherapy derived from a herpes simplex virus-1 genetically engineered to infect and replicate within melanoma cells and to produce GM-CSF for unresectable melanoma	GTMP	16-Dec-2015	Granted MA under additional monitoring	<a href="#">Click Here for Link to EMA Website</a>
<b>HOLOCLAR (Chiesi Farmaceutici S.p.A.)</b>	Ex vivo expanded autologous human corneal epithelial cells containing stem cells for severe limbal stem cell deficiency	SCTMP	17-Feb-2015	Granted MA under conditional approval	<a href="#">Click Here for Link to EMA Website</a>

**ATMP:** Advanced Therapy Medicinal Product // **TEP:** Tissue Engineered Product // **GTMP:** Gene Therapy Medicinal Product // **SCTMP:** Somatic Cell Therapy Medicinal Product // **EC:** European Commission

### List of Cell/Tissue/Gene Products with MA Withdrawn or Suspended in the European Union by European Medicines Agency (EMA)

Name (MA Holder)	Product description and indication(s)	ATMP	Date of MA	Current Status	Additional information
<b>PROVENGE (Dendreon)</b>	Autologous peripheral-blood mononuclear cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor for metastatic prostate cancer	SCTMP	6-Sep-2013	Granted MA under additional monitoring. Withdrawn: Company announced Bankruptcy in 2015	<a href="#">Click Here for Link to EMA Website</a>
<b>MACI (Aastrom Biosciences, Inc.)</b>	Matrix applied characterised autologous cultured chondrocytes for repairing knee cartilage defects	TEP	27-Jun-2013	Granted MA under additional monitoring. MA suspended: 25-Sept-2014	<a href="#">Click Here for Link to EMA Website</a>
<b>GLYBERA (uniQure biopharma BV)</b>	Alipogene tiparvovec (human lipoprotein lipase gene variant in a adeno-associated viral vector) for adult patients with familial lipoprotein lipase deficiency	GTMP	25-Oct-2012	Granted MA under additional monitoring. Withdrawn: MA expired on 25-Oct-2017. The company did not apply for renewal due to the lack of demand	<a href="#">Click Here for Link to EMA Website</a>
<b>CHONDROCELECT (TiGenix NV)</b>	Characterised viable autologous cartilage cells expanded ex vivo for repairing knee cartilage defects	TEP	5-Oct-2009	The product was reimbursed in 3 countries. Withdrawn: 30-Nov-2016. Requested by the company for commercial reasons	<a href="#">Click Here for Link to EMA Website</a>

## List of Cell/Tissue/Gene products with MA in India by Drug Controller General of India (DCGI)

Name (MA Holder)	Product description and indication(s)	Product category	Date of MA	Current Status	Additional information
<b>CARTIGROW™ (Chondron ACI) (RMS Regrow)</b>	Autologous cultured cartilage cells for treatment of articular cartilage defects	Cell Therapy Product	Apr-2017	Conditional approval, post market surveillance study required (50 subjects)	<a href="#">Click Here</a>
<b>OSSGROW™ (Ossron ABI) (RMS Regrow)</b>	Autologous cultured osteoblasts for avascular necrosis of hip	Cell Therapy Product	Apr-2017	Conditional approval, post market surveillance study required (50 subjects)	
<b>APCEDEN (APAC Biotech)</b>	Autologous monocyte-derived mature dendritic cells for treatment of prostate, ovarian, colorectal and non-small cell lung carcinoma	Cell Therapy Product	Mar-2017	Conditional approval, post market surveillance study required	<a href="#">Click Here</a>
<b>Stempeucel® (Stempeutics Research)</b>	Ex-vivo cultured adult allogeneic mesenchymal stromal cells for treatment of critical limb ischemia due to Thromboangiitis Obliterans (Buerger's disease)	Cell Therapy Product	May 2016	In market, limited release (200 patients on a cost recovery basis), post market surveillance study required	<a href="#">Click Here</a>

## List of Cell/Tissue/Gene products with MA in Japan by PMDA (Pharmaceuticals and Medical Devices Agency)

Name (MA Holder)	Product description and indication(s)	Product category	Date of MA	Current Status	Additional information (In Japanese)
<b>KYMRIAH (tisagenlecleucel) (Novartis Pharmaceuticals Corporation)</b>	CD19-directed genetically modified autologous T-cell immunotherapy indicated for the treatment of pediatric and young adult patients up to 25 years with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse and for the treatment of adult patients relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy	Gene Therapy Product	May 2019	In market	<a href="#">Click Here for Link to PMDA Website</a>

<b>Collategene (AnGes, Inc.)</b>	DNA plasmid which encodes human Hepatocyte Growth Factor (HGF) gene for treatment of patients with critical limb ischemia (CLI)	Gene Therapy Product	March 2019	In market, conditional approval	<a href="#">Click Here for Link to PMDA Website</a>
<b>Stemirac</b>	Expanded autologous mesenchymal stromal cells for treatment of spinal cord injury	Cell Therapy Product	December 2018	In market, conditional approval	<a href="#">Click Here for Link to PMDA Website</a>
<b>Temcell HS (JCR Pharmaceuticals Co. Ltd.)</b>	Allogeneic mesenchymal stromal cells for treatment of acute graft versus host disease (aGVHD)	Cell Therapy Product	September 2015	In market	<a href="#">Click Here for Link to PMDA Website</a>
<b>HeartSheet (Terumo Corporation, Ltd.)</b>	Autologous skeletal myoblast sheet product for the treatment of severe heart failure	Tissue Engineered Product	September 2015	Conditional approval	<a href="#">Click Here for Link to PMDA Website</a>
<b>JACC (J-TEC)</b>	Autologous cultured cartilage	Tissue Engineered Product	July 2012	Still in market, previous authorization was as medical device	<a href="#">Click Here for Link to PMDA Website</a>
<b>JACE (J-TEC)</b>	Autologous cultured epidermis for treatment of severe burns	Tissue Engineered Product	October 2007	Still in market, previous authorization was as medical device	<a href="#">Click Here for Link to PMDA Website</a>

### List of Cell/Tissue/Gene Products with MA in New Zealand by MEDSAFE (Medicines and Medical Devices Safety Authority)

Name (MA Holder)	Product description and indication(s)	Product category	Date of MA	Current Status	Additional information
<b>Prochymal (Osiris Therapeutics Incorporated.)</b>	Allogeneic ex-vivo cultured adult human mesenchymal stem cells indicated for the rescue of patients NLT 6 months to 17 years of age with acute graft versus host disease (aGvHD), refractory to treatment with systemic corticosteroid therapy or other immunosuppressive agents	Cell Therapy Product	14-Jun-2012	Approval lapsed	<a href="#">Click Here for Link to MEDSAFE Website</a>

### List of Cell/Tissue/Gene Products with MA in South Korea by MFDS (Ministry of Food and Drug Safety)

Name (MA Holder)	Product description and indication(s)	Product category	Date of MA	Current Status	Additional information
<b>Rosmir® (Tego Science, Inc)</b>	Injectable autologous fibroblasts for improvement of nasojugal groove (a.k.a. tear trough)	Cell Therapy Product	27-Dec-2017	Still in market	<a href="#">Click Here for Link to MFDS Website</a>
<b>INVOSSA®-K (Kolon Life Science, Inc.)</b>	Non-transduced and retrovirally transduced allogeneic chondrocytes to overexpress Transforming Growth Factor-β1 (TGF-β1) in 3:1 ratio for treatment of moderate knee osteoarthritis (Kellgren & Lawrence grade 3)	Gene Therapy Product	12-Jul-2017	License revoked on 28-May-2019	<a href="#">Click Here for Link to MFDS Website</a>
<b>KeraHeal-Allo™ (Biosolution Co., Ltd.)</b>	Composite cell product (allogeneic skin-derived keratinocytes suspended in a thermosensitive hydrogel) for deep 2nd degree burns	Cell Therapy Product	16-Oct-2015	Still in market	<a href="#">Click Here for Link to MFDS Website</a>
<b>NEURONATA-R® (Corestem, Inc.)</b>	Autologous bone marrow mesenchymal stem cell therapy for Amyotrophic Lateral Sclerosis	Cell Therapy Product	30-Jul-2014	Orphan product	<a href="#">Click Here for Link to MFDS Website</a>
<b>Cupistem® (Anterogen)</b>	Autologous adipose tissue-derived mesenchymal stem cell for Crohn's fistula	Cell Therapy Product	18-Jan-2012	Covered by insurance as of January 2014, orphan product	<a href="#">Click Here for Link to MFDS Website</a>
<b>CARTISTEM® (Medipost Co., Ltd.)</b>	Human Umbilical Cord Blood-derived Mesenchymal Stem Cells for the treatment of knee articular cartilage defects in patients with osteoarthritis (ICRS grade IV)	Cell Therapy Product	18-Jan-2012	Still in market	<a href="#">Click Here for Link to MFDS Website</a>
<b>Cellgram®-AMI (Pharmicell Co., Ltd.)</b>	Autologous Bone Marrow-derived Mesenchymal Stem Cells for Acute Myocardial Infarction patients (improvement of LVEF(Left Ventricular Ejection Fraction))	Cell Therapy Product	1-Jul-2011	Name at time of approval was Hearticellgram®-AMI, still in market	<a href="#">Click Here for Link to MFDS Website</a>
<b>CureSkin Inj. (S.Biomedics Co., Ltd.)</b>	Autologous dermal fibroblasts (Depressed acne scar)	Cell Therapy Product	11-May-2010	Still in market	<a href="#">Click Here for Link to MFDS Website</a>
<b>Queencell® (Anterogen)</b>	Autologous adipose tissue-derived adipose cell by minimal manipulation for subcutaneous tissue defect	Cell Therapy Product	26-Mar-2010	Still in market	<a href="#">Click Here for Link to MFDS Website</a>
<b>Kaloderm® (Tego Science, Inc)</b>	Allogeneic keratinocytes (cell sheet) for deep 2nd degree burn or diabetic foot ulcer	Tissue Engineered Product	21-Mar-2005 (2nd degree burn) 24-Jun-2010	Still in market	<a href="#">Click Here for Link to MFDS Website</a>



(Diabetic foot ulcer)

<b>RMS Ossron™ (Sewon Cellontech Co., Ltd.)</b>	Cultured Autologous Osteoblasts for focal bone formation, can be used with or without fibrin glue	Cell Therapy Product	26-Aug-2009	Still in market	<a href="#">Click Here for Link to MFDS Website</a>
<b>Immuncell-LC (GC Cell Corp.)</b>	Autologous activated T-cell for liver cancer (hepatocellular carcinoma)	Cell Therapy Product	6-Aug-2007	Currently in market for hepatocellular carcinoma and in clinical trials for newly diagnosed glioblastoma (Phase III, completed) advanced pancreatic cancer (Phase II, completed)	<a href="#">Click Here for Link to MFDS Website</a>
<b>CreaVax-RCC® (JW CreaGene Corporation)</b>	Autologous Dendritic Cells for Metastatic Renal Cell Carcinoma	Cell Therapy Product	15-May-2007	Received tentative approval in 2007 and product manufacture license as export product in 2013 from MFDS.	<a href="#">Click Here for Link to MFDS Website</a>
<b>KeraHeal® (Biosolution Co., Ltd.)</b>	Autologous skin-derived keratinocytes for deep 2nd degree burns that cover more than 30% of TBSA and 3rd degree burns that cover more than 10% of TBSA	Cell Therapy Product	3-May-2006	Still in market	<a href="#">Click Here for Link to MFDS Website</a>
<b>Holoderm® (Tego Science, Inc)</b>	Autologous keratinocytes for deep 2nd degree burns that cover more than 30% of TBSA and 3rd degree burns that cover more than 10% of TBSA	Tissue Engineered Product	10-Dec-2002	Still in market, reimbursed by insurance	<a href="#">Click Here for Link to MFDS Website</a>
<b>Chondron™ (Sewon Cellontech Co., Ltd.)</b>	Cultured Autologous Chondrocytes for focal cartilage defect of knee, can be used with or without fibrin glue	Cell Therapy Product	30-Jan-2001	Still in market	<a href="#">Click Here for Link to MFDS Website</a>

## List of Cell/Tissue/Gene products with MA in Switzerland by Swissmedic

Name (MA Holder)	Product description and indication(s)	Product category	Date of MA	Current Status	Additional information
<b>Yescarta (Gilead Sciences Switzerland Sàrl)</b>	CD19-directed genetically modified autologous T cell immunotherapy	Gene Therapy Product	17-Apr-2019	Still in Market	<a href="#">Click Here for Link to Swissmedic website</a>



	indicated for the treatment of adult patients with relapsed or refractory DLBCL and PMBCL, after two or more lines of systemic therapy				
<b>Spherox (co.don schweiz GmbH)</b>	Spheroids of human autologous matrix-associated chondrocytes for knee-repairing cartilage defects	Tissue Engineered Product	27-Mar-2019	Still in market	<a href="#">Click Here for Link to Swissmedic website</a>
<b>Alofisel (Takeda Pharma AG)</b>	Expanded allogeneic adipose stem cells as a suspension for injection for the treatment of Crohn's associated complex perianal fistulas in adult patients with non-active or mild-grade Crohn's disease	Cell Therapy Product	27-Dec-2018	Still in market	<a href="#">Click Here for Link to Swissmedic website</a>
<b>Kymriah (Novartis Pharma)</b>	CD19-directed genetically modified autologous T-cell immunotherapy indicated for the treatment of pediatric and young adult patients up to 25 y of age with B-cell ALL that is refractory, in relapse post-transplantation or in second or later relapse, and for the treatment of adult patients with relapsed or refractory DLBCL after two or more lines of systemic therapy	Gene Therapy Product	18-Oct-2018	Still in Market	<a href="#">Click Here for Link to Swissmedic website</a>
<b>Novocart 3D (B. Braun Medical)</b>	Surgical therapy for the biological reconstruction of articular cartilage defects of the knee joint by means of carrier-coupled autologous cartilage cell transplantation (ATC).	Tissue Engineered Product	2-Oct-2014	Still in Market	<a href="#">Click Here for Link to Swissmedic website</a>

**List of Cell/Tissue/Gene Products with MA in the United States by US-FDA (United States Food and Drug Administration)**

<b>Name (MA Holder)</b>	<b>Product description and indication(s)</b>	<b>Product category</b>	<b>Date of MA</b>	<b>Current Status</b>	<b>Additional information</b>
<b>ZOLGENSMA (AveXis, Inc)</b>	Gene therapy product for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.	Gene Therapy Product	24-May-2019	Still in market	<a href="#">Click Here for Link to FDA Website</a>
<b>HPC, Cord Blood (MD Anderson Cord Blood Bank)</b>	For use in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment	Cell Therapy Product	06-Jun-2018	Still in market	<a href="#">Click Here for Link to FDA Website</a>
<b>LUXTURN A (voretigene neparvovec-rzyl) (Spark Therapeutics, Inc.)</b>	Adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy	Gene Therapy Product	19-Dec-2017	Still in market	<a href="#">Click Here for Link to FDA Website</a>
<b>YESCARTA (axicabtagene ciloleucel) (Kite Pharma, Incorporated)</b>	A CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma	Gene Therapy Product	18-Oct-2017	Still in market	<a href="#">Click Here for Link to FDA Website</a>
<b>KYMRIAH (tisagenlecleucel) (Novartis Pharmaceuticals Corporation)</b>	CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse	Gene Therapy Product	30-Aug-2017	Still in market	<a href="#">Click Here for Link to FDA Website</a>

<b>MACI (Vericel Corporation)</b>	Autologous Cultured Chondrocytes on a Porcine Collagen Membrane for the repair of single or multiple symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults	Tissue Engineered Product	13-Dec-2016	Still in market	<a href="#">Click Here for Link to FDA Website</a>
<b>Clevecord (HPC, Cord Blood) (Cleveland Cord Blood Center)</b>	For use in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment	Cell Therapy Product	1-Sep-2016	Still in market	<a href="#">Click Here for Link to FDA Website</a>
<b>HPC, Cord Blood (Bloodworks)</b>	For use in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment	Cell Therapy Product	28-Jan-2016	Still in market	<a href="#">Click Here for Link to FDA Website</a>
<b>IMLYGIC (talimogene laherparepvec) (Amgen Inc.)</b>	Genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery	Gene Therapy Product	27-Oct-2015	Still in market	<a href="#">Click Here for Link to FDA Website</a>
<b>HPC, Cord Blood (LifeSouth Community Blood Centers, Inc.)</b>	For use in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment	Cell Therapy Product	13-Jun-2013	Still in market	<a href="#">Click Here for Link to FDA Website</a>

<b>ALLOCORD (SSM Cardinal Glennon Children's Medical Center)</b>	For use in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment	Cell Therapy Product	30-May-2013	Still in market	<a href="#">Click Here for Link to FDA Website</a>
<b>Ducord (HPC, Cord Blood) (Duke University School of Medicine)</b>	For use in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment	Cell Therapy Product	4-Oct-2012	Still in market	<a href="#">Click Here for Link to FDA Website</a>
<b>HPC, Cord Blood (Clinimmune Labs, University of Colorado Cord Blood Bank)</b>	For use in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment	Cell Therapy Product	24-May-2012	Still in market	<a href="#">Click Here for Link to FDA Website</a>
<b>GINTUIT (Organogenesis, Inc.)</b>	Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen (cellular sheets) for topical (non-submerged) application to a surgically created vascular wound bed in the treatment of mucogingival conditions in adults	Tissue Engineered Product	9-Mar-2012	Still in market	<a href="#">Click Here for Link to FDA Website</a>
<b>Hemacord (HPC, Cord Blood) (New York Blood Center, Inc.)</b>	For use in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment	Cell Therapy Product	1-Nov-2011	Still in market	<a href="#">Click Here for Link to FDA Website</a>

<b>Laviv® (Azcifel-T) (Fibrocell Technologies, Inc.)</b>	Autologous fibroblasts for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults	Cell Therapy Product	21-Jun-2011	Still in market	<a href="#">Click Here for Link to FDA Website</a>
<b>PROVENGE (sipuleucel-T) (Dendreon Corporation)</b>	Autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer	Cell Therapy Product	29-Apr-2010	Still in market	<a href="#">Click Here for Link to FDA Website</a>

**List of Cell/Tissue/Gene Products with Regenerative Medicine Advanced Therapy (RMAT) Designation [4] in the United States** by US-FDA (United States Food and Drug Administration, August 2018)

<b>Name (MA Holder)</b>	<b>Product description and indication(s)</b>	<b>Product category</b>	<b>Date of RMAT Designation</b>	<b>Additional designations</b>	<b>Additional information</b>
<b>SB-525 (Sangamo Therapeutics, Inc. and Pfizer, Inc.)</b>	A recombinant adeno-associated virus serotype 6 vector (AAV6) encoding the complementary deoxyribonucleic acid for B domain deleted human FVIII for the treatment of severe hemophilia A	Gene Therapy Product	05-July-2019	Orphan Drug; Fast Track	<a href="#">Press Release</a>
<b>KB103 (Krystal Biotech, Inc.)</b>	Replication-defective, non-integrating viral vector that has been engineered to deliver functional human COL7A1 genes directly to the patients' skin cells for treatment of dystrophic epidermolysis bullosa (DEB)	Gene therapy product	24-June-2019		<a href="#">Press Release</a>
<b>Viralym-M (ALVR105) (AlloVir)</b>	Allogeneic, off-the-shelf, multi-virus specific T-cell therapy, for the treatment of hemorrhagic cystitis (HC) caused by BK virus in adults and children following allogeneic hematopoietic stem cell transplantation (HSCT)	Cell Therapy Product	11-June-2019		<a href="#">Press Release</a>
<b>FCX-007 (Fibrocell Science, Inc.)</b>	Genetically-modified autologous fibroblasts for the treatment of RDEB, a congenital and progressive orphan skin disease caused by the deficiency of the protein COL7	Gene Therapy Product	29-May-2019	Orphan Drug; Rare Pediatric Disease; Fast Track	<a href="#">Press Release</a>
<b>ECT-001 (ExCellThera)</b>	Hematologic malignancies	Cell Therapy Product	23-Apr-2019		<a href="#">Press Release</a>

<b>FCR001 (Talaris Therapeutics)</b>	Allogeneic cell therapy to induce or restore living donor kidney transplant (LDKT) recipient immune tolerance	Cell Therapy Product	18-Apr-2019	Orphan Drug	<a href="#">Press Release</a>
<b>RP-L102 (Rocket Pharmaceuticals, Inc.)</b>	Lentiviral vector (LVV)-based gene therapy for the treatment of Fanconi Anemia (FA)	Gene therapy product	27-Nov-2018	Fast Track	<a href="#">Press Release</a>
<b>lifileucel (Iovance Biotherapeutics, Inc.)</b>	Adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) for metastatic melanoma	Cell Therapy Product	06-Nov-2018		<a href="#">Press Release</a>
<b>P-BCMA-101 (Poseida Therapeutics Inc.)</b>	Autologous CAR-T therapy targeting cells that express B cell maturation antigen, or BCMA, to treat patients with relapsed/refractory multiple myeloma	Gene Therapy Product	5-Nov-2018		<a href="#">Press Release</a>
<b>Avance<sup>®</sup> Nerve Graft (AxoGen, Inc.)</b>	Off-the-shelf processed human nerve allograft intended for the surgical repair of peripheral nerve discontinuities.	Cell Therapy Product	29-Oct-2018		<a href="#">Press Release</a>
<b>AT132 (Audentes Therapeutics, Inc.)</b>	AAV-mediated gene therapy for the treatment of X-linked Myotubular Myopathy (XLMTM), a rare monogenic disease caused by mutations in the MTM1 gene	Gene Therapy Product	21-Aug-2018	Rare Pediatric Disease; Fast Track; Orphan Drug	<a href="#">Press Release</a>
<b>Romyelocel-L (Cellerant Therapeutics, Inc.)</b>	Off-the-shelf human myeloid progenitor cells for the prevention of serious bacterial and fungal infections in patients with de novo acute myeloid leukemia (AML) undergoing induction chemotherapy	Cell Therapy Product	02-Jul-2018		<a href="#">Press Release</a>
<b>VY-AADC (Voyager Therapeutics, Inc.)</b>	AAV-mediated gene therapy for the treatment of Parkinson's disease in patients with motor fluctuations that are refractory to medical management	Gene Therapy Product	21-Jun-2018		<a href="#">Press Release</a>
<b>CLBS14-RfA (Caladrius Biosciences, Inc.)</b>	CD34+ cell therapy program for the treatment of refractory angina	Cell Therapy Product	19-Jun-2018		<a href="#">Press Release</a>
<b>NSR-REP1 (Nightstar Therapeutics plc)</b>	AAV-mediated gene therapy for the treatment of choroideremia, a rare, degenerative, genetic retinal disorder that leads to blindness	Gene Therapy Product	14-Jun-2018		<a href="#">Press Release</a>
<b>VM202 (ViroMed Co.)</b>	DNA-based drug designed to produce two isoforms of HGF (hepatocyte growth factor) for the treatment of painful diabetic peripheral neuropathy	Gene Therapy Product	May 2018		<a href="#">Press Release</a>
<b>ABO-102 (Abeona Therapeutics Inc.)</b>	AAV-mediated gene therapy for the treatment of Sanfilippo syndrome Type A (MPS IIIA), a	Gene Therapy Product	23-Apr-2018		<a href="#">Press Release</a>

	rare autosomal-recessive lysosomal storage disease				
<b>AmnioFix® (MiMedx)</b>	Allogeneic micronized dehydrated human amnion/chorion membrane for use in the treatment of Osteoarthritis (OA) of the knee	Tissue Engineered Product	9-Mar-2018		<a href="#">Press Release</a>
<b>CAP-1002 (Capricor Therapeutics)</b>	Allogeneic cell therapy (cardiosphere-derived cells) that is currently in clinical development for the treatment of Duchenne muscular dystrophy	Cell Therapy Product	5-Feb-2018	Orphan Drug; Rare Pediatric Disease	<a href="#">Press Release</a>
<b>EB-101 (Abeona Therapeutics Inc.)</b>	Gene-corrected autologous cell therapy product for patients with recessive dystrophic epidermolysis bullosa (RDEB)	Gene Therapy Product	29-Jan-2018	Breakthrough therapy; Orphan Drug; Rare Pediatric Disease	<a href="#">Press Release</a>
<b>Revascor (MPC-150-IM) (Mesoblast Limited)</b>	Mesenchymal precursor cell (MPC) therapy in the treatment of heart failure patients with left ventricular systolic dysfunction and left ventricular assist devices (LVADs)	Cell Therapy Product	21-Dec-2017		<a href="#">Press Release</a>
<b>MPC therapy (Mesoblast Limited)</b>	Mesenchymal precursor cell (MPC) therapy in the treatment of heart failure patients with left ventricular systolic dysfunction and left ventricular assist devices (LVADs)	Cell Therapy Product	21-Dec-2017		<a href="#">Press Release</a>
<b>CEVA101 (Cellvation)</b>	Autologous bone marrow-derived stem cells for the treatment of traumatic brain injury	Cell Therapy Product	8-Nov-2017		<a href="#">Press Release</a>
<b>Multistem (Athersys)</b>	Proprietary stem cell product for the treatment of ischemic stroke	Cell Therapy Product	5-Oct-2017		<a href="#">Press Release</a>
<b>AST-OPC1 (Asterias Biotherapeutics)</b>	Oligodendrocyte progenitor cells manufactured from pluripotent embryonic stem cell for treatment of spinal cord injury patients	Cell Therapy Product	2-Oct-2017		<a href="#">Press Release</a>
<b>LentiGlobin® BB305 (Bluebird Bio)</b>	Ex-vivo modified autologous hematopoietic stem cells for treatment of transfusion-dependent $\beta$ -thalassemia (also known as $\beta$ -thalassemia major) and severe sickle cell disease (SCD)	Gene Therapy Product	1-Oct-2017		<a href="#">Press Release</a>
<b>ATIR101™ (Kiadis Pharma)</b>	Adjunctive immunotherapeutic on top of allogeneic hematopoietic stem cell transplantation (HSCT)	Cell Therapy Product	20-Sep-2017		<a href="#">Press Release</a>



<b>StrataGraft (Mallinckrodt plc)</b>	Autologous skin cell product for the treatment of deep partial thickness burns	Tissue Engineered Product	18-Jul-2017		<a href="#">Press Release</a>
<b>Ixmyelocel-T (Vericel)</b>	Autologous expanded multicellular (mesenchymal cells, monocytes and alternatively activated macrophages) product for the treatment of patients with advanced heart failure due to ischemic dilated cardiomyopathy	Cell Therapy Product	10-May-2017		<a href="#">Press Release</a>
<b>jCell (jCyte)</b>	Adult retinal progenitor cells for the treatment of retinitis pigmentosa (RP)	Cell Therapy Product	2-May-2017		<a href="#">Press Release</a>
<b>RVT-802 (Enzyvant)</b>	Allogeneic thymic tissue for the treatment of primary immune deficiency resulting from complete diGeorge Syndrome (cDGS)	Cell Therapy Product	17-Apr-2017	Breakthrough Therapy, Rare Pediatric Disease, Orphan Drug	<a href="#">Press Release</a>
<b>HUMACYL® (Humacyte)</b>	Human acellular vessel (HAV) for patients undergoing hemodialysis	Tissue Engineered Product	20-Mar-2017		<a href="#">Press Release</a>
<b>JCAR017 (Juno Therapeutics)</b>	Treatment of r/r aggressive large B-cell Non-Hodgkin Lymphoma	Gene Therapy Product			